rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2024-377-384rsp-3603Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESВолчаночный нефрит: современные представления о терапии. (Часть II)Lupus nephritis. Part II, modern ideas about therapyhttps://orcid.org/0000-0002-1663-7810АсееваЕ. А.AseevaElena A.

Асеева Елена Александровна

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

eaasseeva@mail.ruhttps://orcid.org/0000-0002-5206-1732СоловьевС. К.SolovyevSergey K.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-4275-0315КозловскаяН. Л.KozlovskayaNatalia L.

117198, Москва, ул. Миклухо-Маклая

117198, Moscow, Miklukho-Maklaya str., 6 

https://orcid.org/0000-0001-7847-1679БарановА. А.BaranovAndrey A.

150000, Ярославль, ул. Революционная, 5

150000, Yaroslavl, Revolyutsionnaya str., 5 

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovEvgeny L.

115522, Москва, Каширское шоссе, 34а

119991, Москва, ул. Трубецкая, 8, стр. 2 

115522, Moscow, Kashirskoye Highway, 34A

119991, Moscow, Trubetskaya str., 8, building 2

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГАОУ ВО «Российский университет дружбы народов имени Патриса Лумумбы»РоссияPeoples’ Friendship University of Russia named after Patrice LumumbaRussian FederationФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава РоссииРоссияYaroslavl State Medical UniversityRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of the Russian Federation (Sechenov University)Russian Federation202402092024624377384Copyright © Асеева Е.А., Соловьев С.К., Козловская Н.Л., Баранов А.А., Насонов Е.Л., 20242024Асеева Е.А., Соловьев С.К., Козловская Н.Л., Баранов А.А., Насонов Е.Л.Aseeva E.A., Solovyev S.K., Kozlovskaya N.L., Baranov A.A., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3603

Во второй части обзора представлены современные данные о стратегии терапии волчаночного нефрита с учетом морфологического класса поражения почек, особенностей течения и активности. Описаны подходы к мониторингу и оценке эффективности лечения, проблемы достижения полного и частичного почечного ответа. Дана характеристика классических и инновационных методов терапии.

The second part of the review presents current data on the treatment strategy for lupus nephritis, considering the morphological class of kidney damage, course and activity. Approaches to monitoring and evaluating the effectiveness of treatment, the problems of achieving a complete and partial renal response are described. The characteristic of classical and innovative methods of therapy is given.

системная красная волчанкаволчаночный нефритлечениеsystemic lupus erythematosuslupus nephritistreatmentСтатья подготовлена по фундаментальной научной теме FURS-2022-003 № 122040400024-07.ReferencesWard MM. Hospital experience and mortality in patients with systemic lupus erythematosus: Which patients benefit most from treatment at highly experienced hospitals? J Rheumatol. 2002;29(6):1198-1206.Ward MM. Hospital experience and mortality in patients with systemic lupus erythematosus: Which patients benefit most from treatment at highly experienced hospitals? J Rheumatol. 2002;29(6):1198-1206.Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al.; European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782. doi: 10.1136/annrheumdis-2012-201940Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al.; European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782. doi: 10.1136/annrheumdis-2012-201940Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ra mon Garrido E, Danieli MG, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004;50(12):3934-3940. doi: 10.1002/art.20666Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ra mon Garrido E, Danieli MG, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004;50(12):3934-3940. doi: 10.1002/art.20666Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ; Collaborative Study Group. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008;3(1):46-53. doi: 10.2215/CJN.03280807Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ; Collaborative Study Group. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008;3(1):46-53. doi: 10.2215/CJN.03280807Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002;46(4):995-1002. doi: 10.1002/art.10142Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002;46(4):995-1002. doi: 10.1002/art.10142Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant. 2007;22(9):2531-2539. doi: 10.1093/ndt/gfm245Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant. 2007;22(9):2531-2539. doi: 10.1093/ndt/gfm245Kostopoulou M, Fanouriakis A, Cheema K, Boletis J, Bertsias G, Jayne D, et al. Management of lupus nephritis: A systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. RMD Open. 2020;6(2):e001263. doi: 10.1136/rmdopen-2020-001263Kostopoulou M, Fanouriakis A, Cheema K, Boletis J, Bertsias G, Jayne D, et al. Management of lupus nephritis: A systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. RMD Open. 2020;6(2):e001263. doi: 10.1136/rmdopen-2020-001263Londoño Jimenez A, Mowrey WB, Putterman C, Buyon J, Goilav B, Broder A. Brief report: Tubulointerstitial damage in lupus nephritis: A comparison of the factors associated with tubulointerstitial inflammation and renal scarring. Arthritis Rheumatol. 2018;70(11):1801-1806. doi: 10.1002/art.40575Londoño Jimenez A, Mowrey WB, Putterman C, Buyon J, Goilav B, Broder A. Brief report: Tubulointerstitial damage in lupus nephritis: A comparison of the factors associated with tubulointerstitial inflammation and renal scarring. Arthritis Rheumatol. 2018;70(11):1801-1806. doi: 10.1002/art.40575Galindo-Izquierdo M, Rodriguez-Almaraz E, Pego-Reigosa JM, López-Longo FJ, Calvo-Alén J, Olivé A, et al.; RELESSER Group, from the Spanish Society of Rheumatology Systemic Autoimmune Diseases Study Group (EASSER). Characterization of patients with lupus nephritis included in a large cohort from the Spanish Society of Rheumatology Registry of Patients with Systemic Lupus Erythematosus (RELESSER). Medicine (Baltimore). 2016;95(9):e2891. doi: 10.1097/MD.0000000000002891Galindo-Izquierdo M, Rodriguez-Almaraz E, Pego-Reigosa JM, López-Longo FJ, Calvo-Alén J, Olivé A, et al.; RELESSER Group, from the Spanish Society of Rheumatology Systemic Autoimmune Diseases Study Group (EASSER). Characterization of patients with lupus nephritis included in a large cohort from the Spanish Society of Rheumatology Registry of Patients with Systemic Lupus Erythematosus (RELESSER). Medicine (Baltimore). 2016;95(9):e2891. doi: 10.1097/MD.0000000000002891Pokroy-Shapira E, Gelernter I, Molad Y. Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: A single-center inception cohort study. Clin Rheumatol. 2014;33(5):649-657. doi: 10.1007/s10067-014-2527-0Pokroy-Shapira E, Gelernter I, Molad Y. Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: A single-center inception cohort study. Clin Rheumatol. 2014;33(5):649-657. doi: 10.1007/s10067-014-2527-0Ассоциация нефрологов, Научное общество нефрологов России, Общероссийская общественная организация нефрологов «Российское диализное общество». Клинические рекомендации. Диагностика и лечение волчаночного нефрита. М.;2021. [Association of Nephrologists, Scientific Society of Nephrologists of Russia, All-Russian Public Organization of Nephrologists “Russian Dialysis Society”. Clinical guidelines. Diagnosis and treatment of lupus nephritis. Moscow;2021. (In Russ.)]. URL: http://nonr.su/wp-content/uploads/2021/09/Диагностика-и-лечение-волчаночного-нефрита-проект.pdf (Accessed: DD Month 2020).Ассоциация нефрологов, Научное общество нефрологов России, Общероссийская общественная организация нефрологов «Российское диализное общество». Клинические рекомендации. Диагностика и лечение волчаночного нефрита. М.;2021. [Association of Nephrologists, Scientific Society of Nephrologists of Russia, All-Russian Public Organization of Nephrologists “Russian Dialysis Society”. Clinical guidelines. Diagnosis and treatment of lupus nephritis. Moscow;2021. (In Russ.)]. URL: http://nonr.su/wp-content/uploads/2021/09/Диагностика-и-лечение-волчаночного-нефрита-проект.pdf (Accessed: DD Month 2020).Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-723. doi: 10.1136/annrheumdis-2020-216924Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-723. doi: 10.1136/annrheumdis-2020-216924Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125(7):549-557. doi: 10.7326/0003-4819-125-7-199610010-00003Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125(7):549-557. doi: 10.7326/0003-4819-125-7-199610010-00003Brugos B, Sebestyen L, Tarr T, Vincze Z. Use of cyclophosphamide and other immunosuppressive drugs in the treatment of patients with lupus nephritis. Pharmazie. 2014;69(6):442-444.Brugos B, Sebestyen L, Tarr T, Vincze Z. Use of cyclophosphamide and other immunosuppressive drugs in the treatment of patients with lupus nephritis. Pharmazie. 2014;69(6):442-444.Mitjavila F, Pac V, Moga I, Poveda R, Vidaller A, Carrera M, et al. Clinicopathological correlations and prognostic factors in lupus nephritis. Clin Exp Rheumatol. 1997;15(6):625-631.Mitjavila F, Pac V, Moga I, Poveda R, Vidaller A, Carrera M, et al. Clinicopathological correlations and prognostic factors in lupus nephritis. Clin Exp Rheumatol. 1997;15(6):625-631.Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14-25. doi: 10.1136/annrheumdis-2020-218272Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14-25. doi: 10.1136/annrheumdis-2020-218272Moroni G, Gatto M, Tamborini F, Quaglini S, Radice F, Saccon F, et al. Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. Ann Rheum Dis. 2020;79(8):1077-1083. doi: 10.1136/annrheumdis-2020-216965Moroni G, Gatto M, Tamborini F, Quaglini S, Radice F, Saccon F, et al. Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. Ann Rheum Dis. 2020;79(8):1077-1083. doi: 10.1136/annrheumdis-2020-216965Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al.; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886-1895. doi: 10.1056/NEJMoa1014460Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al.; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886-1895. doi: 10.1056/NEJMoa1014460Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, et al. The frequency and outcome of lupus nephritis: Results from an international inception cohort study. Rheumatology (Oxford). 2016;55(2):252-262. doi: 10.1093/rheumatology/kev311Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, et al. The frequency and outcome of lupus nephritis: Results from an international inception cohort study. Rheumatology (Oxford). 2016;55(2):252-262. doi: 10.1093/rheumatology/kev311Moroni G, Gatto M, Raffiotta F, Binda V, Frangou E, Lightstone L, et al. Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate. Autoimmun Rev. 2018;17(1):11-18. doi: 10.1016/j.autrev.2017.11.003Moroni G, Gatto M, Raffiotta F, Binda V, Frangou E, Lightstone L, et al. Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate. Autoimmun Rev. 2018;17(1):11-18. doi: 10.1016/j.autrev.2017.11.003Grootscholten C, Berden JHM. Discontinuation of immunosuppression in proliferative lupus nephritis: Is it possible? Nephrol Dial Transplant. 2006;21:1465-1469. doi: 10.1093/ndt/gfl208Grootscholten C, Berden JHM. Discontinuation of immunosuppression in proliferative lupus nephritis: Is it possible? Nephrol Dial Transplant. 2006;21:1465-1469. doi: 10.1093/ndt/gfl208van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. doi: 10.1136/annrheumdis-2013-205139van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. doi: 10.1136/annrheumdis-2013-205139Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: Trends over time and major contributors. Rheumatology. 2020;59:29-38. doi: 10.1093/rheumatology/keaa382Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: Trends over time and major contributors. Rheumatology. 2020;59:29-38. doi: 10.1093/rheumatology/keaa382Laskari K, Tzioufas AG, Antoniou A, Moutsopoulos HM. Longterm followup after tapering mycophenolate mofetil during maintenance treatment for proliferative lupus nephritis. J Rheumatol. 2011;38:1304-1308. doi: 10.3899/jrheum.101249Laskari K, Tzioufas AG, Antoniou A, Moutsopoulos HM. Longterm followup after tapering mycophenolate mofetil during maintenance treatment for proliferative lupus nephritis. J Rheumatol. 2011;38:1304-1308. doi: 10.3899/jrheum.101249Kostopoulou M, Mukhtyar CB, Bertsias G, Boumpas DT, Fanouriakis A. Management of systemic lupus erythematosus: A systematic literature review informing the 2023 update of the EULAR recommendations. Ann Rheum Dis. 2024 May 22:ard-2023-225319. doi: 10.1136/ard-2023-225319Kostopoulou M, Mukhtyar CB, Bertsias G, Boumpas DT, Fanouriakis A. Management of systemic lupus erythematosus: A systematic literature review informing the 2023 update of the EULAR recommendations. Ann Rheum Dis. 2024 May 22:ard-2023-225319. doi: 10.1136/ard-2023-225319Jourde-Chiche N, Costedoat-Chalumeau N, Baumstarck K, Loundou A, Bouillet L, Burtey S, et al.; WIN-Lupus study group. Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): Results of a multicentre randomised controlled trial. Ann Rheum Dis. 2022;81(10):1420-1427. doi: 10.1136/annrheumdis-2022-222435Jourde-Chiche N, Costedoat-Chalumeau N, Baumstarck K, Loundou A, Bouillet L, Burtey S, et al.; WIN-Lupus study group. Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): Results of a multicentre randomised controlled trial. Ann Rheum Dis. 2022;81(10):1420-1427. doi: 10.1136/annrheumdis-2022-222435Anutrakulchai S, Panaput T, Wongchinsri J, Chaishayanon S, Satirapoj B, Traitanon O, et al. A multicentre, randomised controlled study of enteric-coated mycophenolate sodium for the treatment of relapsed or resistant proliferative lupus nephritis: An Asian experience. Lupus Sci Med. 2016;3(1):e000120. doi: 10.1136/lupus-2015-000120Anutrakulchai S, Panaput T, Wongchinsri J, Chaishayanon S, Satirapoj B, Traitanon O, et al. A multicentre, randomised controlled study of enteric-coated mycophenolate sodium for the treatment of relapsed or resistant proliferative lupus nephritis: An Asian experience. Lupus Sci Med. 2016;3(1):e000120. doi: 10.1136/lupus-2015-000120Rivera F, Mérida E, Illescas ML, López-Rubio E, Frutos MA, García-Frías P, et al.; Glomerular Spanish Glomerular Study Group (GLOSEN). Mycophenolate in refractory and relapsing lupus nephritis. Am J Nephrol. 2014;40(2):105-112. doi: 10.1159/000365256Rivera F, Mérida E, Illescas ML, López-Rubio E, Frutos MA, García-Frías P, et al.; Glomerular Spanish Glomerular Study Group (GLOSEN). Mycophenolate in refractory and relapsing lupus nephritis. Am J Nephrol. 2014;40(2):105-112. doi: 10.1159/000365256Choi CB, Won S, Bae SC. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. Lupus. 2018;27(6):1007-1011. doi: 10.1177/0961203318758505Choi CB, Won S, Bae SC. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. Lupus. 2018;27(6):1007-1011. doi: 10.1177/0961203318758505Mok CC, To CH, Yu KL, Ho LY. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: A 12-month prospective study. Lupus. 2013;22(11):1135-1141. doi: 10.1177/0961203313502864Mok CC, To CH, Yu KL, Ho LY. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: A 12-month prospective study. Lupus. 2013;22(11):1135-1141. doi: 10.1177/0961203313502864Kasitanon N, Boripatkosol P, Louthrenoo W. Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria. Int J Rheum Dis. 2018;21(1):200-207. doi: 10.1111/1756-185X.13152Kasitanon N, Boripatkosol P, Louthrenoo W. Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria. Int J Rheum Dis. 2018;21(1):200-207. doi: 10.1111/1756-185X.13152Zhang J, Zhao Z, Hu X. Effect of rituximab on serum levels of anti-c1q and antineutrophil cytoplasmic autoantibodies in refractory severe lupus nephritis. Cell Biochem Biophys. 2015;72:197-201. doi: 10.1007/s12013-014-0437-zZhang J, Zhao Z, Hu X. Effect of rituximab on serum levels of anti-c1q and antineutrophil cytoplasmic autoantibodies in refractory severe lupus nephritis. Cell Biochem Biophys. 2015;72:197-201. doi: 10.1007/s12013-014-0437-zContis A, Vanquaethem H, Truchetet ME, Couzi L, Rigothier C, Richez C, et al. Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: A chart review. Clin Rheumatol. 2016;35(2):517-522. doi: 10.1007/s10067-015-3166-9Contis A, Vanquaethem H, Truchetet ME, Couzi L, Rigothier C, Richez C, et al. Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: A chart review. Clin Rheumatol. 2016;35(2):517-522. doi: 10.1007/s10067-015-3166-9Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, et al. AURA-LV Study Group. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95(1):219-231. doi: 10.1016/j.kint.2018.08.025Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, et al. AURA-LV Study Group. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95(1):219-231. doi: 10.1016/j.kint.2018.08.025Li Y, Palmisano M, Sun D, Zhou S. Pharmacokinetic disposition difference between cyclosporine and voclosporin drives their distinct efficacy and safety profiles in clinical studies. Clin Pharmacol. 2020;12:83-96. doi: 10.2147/CPAA.S255789Li Y, Palmisano M, Sun D, Zhou S. Pharmacokinetic disposition difference between cyclosporine and voclosporin drives their distinct efficacy and safety profiles in clinical studies. Clin Pharmacol. 2020;12:83-96. doi: 10.2147/CPAA.S255789Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, et al.; AURA-LV Study Group. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95(1):219-231. doi: 10.1016/j.kint.2018.08.025Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, et al.; AURA-LV Study Group. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95(1):219-231. doi: 10.1016/j.kint.2018.08.025Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al.; BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833-1838. doi: 10.1136/annrheumdis-2011-200831Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al.; BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833-1838. doi: 10.1136/annrheumdis-2011-200831Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731. doi: 10.1016/S0140-6736(10)61354-2Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731. doi: 10.1016/S0140-6736(10)61354-2Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117-1128. doi: 10.1056/NEJMoa2001180Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117-1128. doi: 10.1056/NEJMoa2001180Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14-25. doi: 10.1136/annrheumdis-2020-218272Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14-25. doi: 10.1136/annrheumdis-2020-218272Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383. doi: 10.47360/1995-4484-2021-367-383Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):367-383 (In Russ.)]. doi: 10.47360/1995-4484-2021-367-383Асеева ЕА, Соловьев СК, Меснянкина АА, Цанян МЭ, Насонов ЕЛ. Опыт применения белимумаба у больных системной красной волчанкой. Научно-практическая ревматология. 2015;53(3):329-335. doi: 10.14412/1995-4484-2015-329-335Aseeva EA, Soloviev SK, Mesnyankina AA, Tsanyan ME, Nasonov EL. Experience with belimumab in patients with systemic lupus erythematosus. NauchnoPrakticheskaya Revmatologia = Rheumatology Science and Practice. 2015;53(3):329-335 (In Russ.)]. doi: 10.14412/1995-4484-2015-329-335Basu B, Roy B, Babu BG. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol. 2017;32(6):1013-1021. doi: 10.1007/s00467-017-3583-xBasu B, Roy B, Babu BG. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol. 2017;32(6):1013-1021. doi: 10.1007/s00467-017-3583-xMoroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study. Rheumatology (Oxford). 2014;53(9):1570-1577. doi: 10.1093/rheumatology/ket462Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study. Rheumatology (Oxford). 2014;53(9):1570-1577. doi: 10.1093/rheumatology/ket462Li K, Yu Y, Gao Y, Zhao F, Liang Z, Gao J. Comparative effectiveness of rituximab and common induction therapies for lupus nephritis: A systematic review and network meta-analysis. Front Immunol. 2022;13:859380. doi: 10.3389/fimmu.2022.859380Li K, Yu Y, Gao Y, Zhao F, Liang Z, Gao J. Comparative effectiveness of rituximab and common induction therapies for lupus nephritis: A systematic review and network meta-analysis. Front Immunol. 2022;13:859380. doi: 10.3389/fimmu.2022.859380Торгашина АВ, Соловьев СК, Александрова ЕН, РаденскаЛоповок СГ, Насонов ЕЛ. Применение ритуксимаба у больных волчаночным нефритом. Научно-практическая ревматология. 2010;48(4):14-26. doi: 10.14412/1995-4484-2010-1161Torgashina AV, Solovyev SK, Aleksandrova EN, Radenska-Lopovok SG, Nasonov EL. Use of rituximab in patients with lupus nephritis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2010;48(4):14-26 (In Russ.)]. doi: 10.14412/1995-4484-2010-1161Цанян МЭ, Соловьев СК, Торгашина АВ, Александрова ЕН, Раденска-Лоповок СГ, Николаева ЕВ, и др. Эффективность терапии ритуксимабом у больных рефрактерной к стандартной терапии системной красной волчанкой при длительном динамическом наблюдении. Научно-практическая ревматология. 2014;52(2):159-168. doi: 10.14412/1995-4484-2014-159-168Tsanyan ME, Soloviev SK, Torgashina AV, Aleksandrova EN, Radenska-Lopovok SG, Nikolaeva EV, et al. Rituximab treatment efficacy in patients with systemic lupus erythematosus refractory to standard therapy in the long-term follow-up. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(2):159-168 (In Russ.)]. doi: 10.14412/1995-4484-2014-159-168Насонов ЕЛ. Перспективы анти-В-клеточной терапии в ревматологии. Научно-практическая ревматология. 2018;56(5):539-548. doi: 10.14412/1995-4484-2018-539-548Nasonov EL. Prospects for anti-B-cell therapy in rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56(5):539-548 (In Russ.)]. doi: 10.14412/1995-4484-2018-539-548Насонов ЕЛ, Авдеева АС. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;57(4):452-461. doi: 10.14412/1995-4484-2019-452-461Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type I interferon: New evidence. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(4):452-461 (In Russ.)]. doi: 10.14412/1995-4484-2019-452-461Rönnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol. 2011;23:113-121. doi: 10.1016/j.smim.2011.01.009Rönnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol. 2011;23:113-121. doi: 10.1016/j.smim.2011.01.009Parikh SV, Rovin BH. Current and emerging therapies for lupus nephritis. J Am Soc Nephrol. 2016;27(10):2929-2939. doi: 10.1681/ASN.2016040415Parikh SV, Rovin BH. Current and emerging therapies for lupus nephritis. J Am Soc Nephrol. 2016;27(10):2929-2939. doi: 10.1681/ASN.2016040415Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2951-2962. doi: 10.1002/art.22044Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2951-2962. doi: 10.1002/art.22044Parikh SV, Malvar A, Song H, Alberton V, Lococo B, Vance J, et al. Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders. Lupus Sci Med. 2015;2(1):e000112. doi: 10.1136/lupus-2015-000112Parikh SV, Malvar A, Song H, Alberton V, Lococo B, Vance J, et al. Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders. Lupus Sci Med. 2015;2(1):e000112. doi: 10.1136/lupus-2015-000112Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al.; TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211-221. doi: 10.1056/NEJMoa1912196Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al.; TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211-221. doi: 10.1056/NEJMoa1912196Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al.; CD1013 Study Investigators. Anifrolumab, an antiinterferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(2):376-386. doi: 10.1002/art.39962Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al.; CD1013 Study Investigators. Anifrolumab, an antiinterferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(2):376-386. doi: 10.1002/art.39962Hu W, Chen Y, Wang S, Chen H, Liu Z, Zeng C, et al. Clinicalmorphological features and outcomes of lupus podocytopathy. Clin J Am Soc Nephrol. 2016;11(4):585-592. doi: 10.2215/CJN.06720615Hu W, Chen Y, Wang S, Chen H, Liu Z, Zeng C, et al. Clinicalmorphological features and outcomes of lupus podocytopathy. Clin J Am Soc Nephrol. 2016;11(4):585-592. doi: 10.2215/CJN.06720615Bomback AS, Markowitz GS. Lupus podocytopathy: A distinct entity. Clin J Am Soc Nephrol. 2016;11(4):547-548. doi: 10.2215/CJN.01880216Bomback AS, Markowitz GS. Lupus podocytopathy: A distinct entity. Clin J Am Soc Nephrol. 2016;11(4):547-548. doi: 10.2215/CJN.01880216Oliva-Damaso N, Payan J, Oliva-Damaso E, Pereda T, Bomback AS. Lupus podocytopathy: An overview. Adv Chronic Kidney Dis. 2019;26(5):369-375. doi: 10.1053/j.ackd.2019.08.011Oliva-Damaso N, Payan J, Oliva-Damaso E, Pereda T, Bomback AS. Lupus podocytopathy: An overview. Adv Chronic Kidney Dis. 2019;26(5):369-375. doi: 10.1053/j.ackd.2019.08.011Lionaki S, Liapis G, Vallianou K, Appel GB, D’Agati VD. The various forms of nephrotic syndrome in a patient with systemic lupus erythematosus. Case Rep Nephrol. 2020;2020:7869216. doi: 10.1155/2020/7869216Lionaki S, Liapis G, Vallianou K, Appel GB, D’Agati VD. The various forms of nephrotic syndrome in a patient with systemic lupus erythematosus. Case Rep Nephrol. 2020;2020:7869216. doi: 10.1155/2020/7869216Dube GK, Markowitz GS, Radhakrishnan J, Appel GB, D’Agati VD. Minimal change disease in systemic lupus erythematosus. Clin Nephrol. 2002;57(2):120-126. doi: 10.5414/cnp57120Dube GK, Markowitz GS, Radhakrishnan J, Appel GB, D’Agati VD. Minimal change disease in systemic lupus erythematosus. Clin Nephrol. 2002;57(2):120-126. doi: 10.5414/cnp57120Hertig A, Droz D, Lesavre P, Grünfeld JP, Rieu P. SLE and idiopathic nephrotic syndrome: Coincidence or not? Am J Kidney Dis. 2002;40(6):1179-1184. doi: 10.1053/ajkd.2002.36875Hertig A, Droz D, Lesavre P, Grünfeld JP, Rieu P. SLE and idiopathic nephrotic syndrome: Coincidence or not? Am J Kidney Dis. 2002;40(6):1179-1184. doi: 10.1053/ajkd.2002.36875Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16(1):175-179. doi: 10.1681/ASN.2004050350Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16(1):175-179. doi: 10.1681/ASN.2004050350Bomback AS. Nonproliferative forms of lupus nephritis: An overview. Rheum Dis Clin North Am. 2018;44(4):561-569. doi: 10.1016/j.rdc.2018.06.003Bomback AS. Nonproliferative forms of lupus nephritis: An overview. Rheum Dis Clin North Am. 2018;44(4):561-569. doi: 10.1016/j.rdc.2018.06.003KDIGO. Clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100:1-276. doi: 10.1016/j.kint.2021.05.021KDIGO. Clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100:1-276. doi: 10.1016/j.kint.2021.05.021Bendapudi PK, Hurwitz S, Fry A, Marques MB, Waldo SW, Li A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: A cohort study. Lancet Haematol. 2017;4(4):e157-e164. doi: 10.1016/S2352-3026(17)30026-1Bendapudi PK, Hurwitz S, Fry A, Marques MB, Waldo SW, Li A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: A cohort study. Lancet Haematol. 2017;4(4):e157-e164. doi: 10.1016/S2352-3026(17)30026-1von Baeyer H. Plasmapheresis in thrombotic microangiopathy associated syndromes: Review of outcome data derived from clinical trials and open studies. Ther Apher. 2002;6(4):320-328. doi: 10.1046/j.1526-0968.2002.00390.xvon Baeyer H. Plasmapheresis in thrombotic microangiopathy associated syndromes: Review of outcome data derived from clinical trials and open studies. Ther Apher. 2002;6(4):320-328. doi: 10.1046/j.1526-0968.2002.00390.xAllford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol. 2003;120(4):556-573. doi: 10.1046/j.1365-2141.2003.04049.xAllford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol. 2003;120(4):556-573. doi: 10.1046/j.1365-2141.2003.04049.xWestwood JP, Thomas M, Alwan F, McDonald V, Benjamin S, Lester WA, et al. Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: Outcome and evaluation of dosing regimens. Blood Adv. 2017;1(15):1159-1166. doi: 10.1182/bloodadvances.2017008268Westwood JP, Thomas M, Alwan F, McDonald V, Benjamin S, Lester WA, et al. Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: Outcome and evaluation of dosing regimens. Blood Adv. 2017;1(15):1159-1166. doi: 10.1182/bloodadvances.2017008268Froissart A, Buffet M, Veyradier A, Poullin P, Provôt F, Malot S, et al.; French Thrombotic Microangiopathies Reference Center. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40(1):104-111. doi: 10.1097/CCM.0b013e31822e9d66Froissart A, Buffet M, Veyradier A, Poullin P, Provôt F, Malot S, et al.; French Thrombotic Microangiopathies Reference Center. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40(1):104-111. doi: 10.1097/CCM.0b013e31822e9d66Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136(3):451-461. doi: 10.1111/j.1365-2141.2006.06448.xScully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136(3):451-461. doi: 10.1111/j.1365-2141.2006.06448.xScully M, McDonald V, Cavenagh J, Longair I, Cohen H, Machin SJ. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118:1746-1753. doi: 10.1182/blood-2011-03-341131Scully M, McDonald V, Cavenagh J, Longair I, Cohen H, Machin SJ. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118:1746-1753. doi: 10.1182/blood-2011-03-341131Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, et al.; TITAN Investigators. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(6):511-522. doi: 10.1056/NEJMoa1505533Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, et al.; TITAN Investigators. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(6):511-522. doi: 10.1056/NEJMoa1505533Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, et al.; HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335-346. doi: 10.1056/NEJMoa1806311Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, et al.; HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335-346. doi: 10.1056/NEJMoa1806311Sciascia S, Yazdany J, Dall’Era M, Fenoglio R, Radin M, Aggarwal I, et al. Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: A multicentre cohort study. Ann Rheum Dis. 2019;78(7):1004-1006. doi: 10.1136/annrheumdis-2018-214559Sciascia S, Yazdany J, Dall’Era M, Fenoglio R, Radin M, Aggarwal I, et al. Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: A multicentre cohort study. Ann Rheum Dis. 2019;78(7):1004-1006. doi: 10.1136/annrheumdis-2018-214559Tektonidou MG. Antiphospholipid syndrome nephropathy: From pathogenesis to treatment. Front Immunol. 2018;9: 1181. doi: 10.3389/fimmu.2018.01181Tektonidou MG. Antiphospholipid syndrome nephropathy: From pathogenesis to treatment. Front Immunol. 2018;9: 1181. doi: 10.3389/fimmu.2018.01181Dufrost V, Risse J, Reshetnyak T, Satybaldyeva M, Du Y, Yan XX, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev. 2018;17(10):1011-1021. doi: 10.1016/j.autrev.2018.04.009Dufrost V, Risse J, Reshetnyak T, Satybaldyeva M, Du Y, Yan XX, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev. 2018;17(10):1011-1021. doi: 10.1016/j.autrev.2018.04.009Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365-1371. doi: 10.1182/blood-2018-04-848333Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365-1371. doi: 10.1182/blood-2018-04-848333Kazzaz NM, McCune WJ, Knight JS. Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol. 2016;28:218-227. doi: 10.1097/BOR.0000000000000269Kazzaz NM, McCune WJ, Knight JS. Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol. 2016;28:218-227. doi: 10.1097/BOR.0000000000000269Kronbichler A, Brezina B, Quintana LF, Jayne DR. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review. Autoimmun Rev. 2016;15(1):38-49. doi: 10.1016/j.autrev.2015.08.010Kronbichler A, Brezina B, Quintana LF, Jayne DR. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review. Autoimmun Rev. 2016;15(1):38-49. doi: 10.1016/j.autrev.2015.08.010Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez-Puerta JA, Ramos-Casals M, et al.; European Forum on Antiphospholipid Antibodies. Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006;54(8):2568-2576. doi: 10.1002/art.22018Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez-Puerta JA, Ramos-Casals M, et al.; European Forum on Antiphospholipid Antibodies. Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006;54(8):2568-2576. doi: 10.1002/art.22018Diószegi Á, Tarr T, Nagy-Vincze M, Nánásy-Vass M, Veisz R, Bidiga L, et al. Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: The beneficial effect of rituximab treatment. Lupus. 2018;27(9):1552-1558. doi: 10.1177/0961203318768890Diószegi Á, Tarr T, Nagy-Vincze M, Nánásy-Vass M, Veisz R, Bidiga L, et al. Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: The beneficial effect of rituximab treatment. Lupus. 2018;27(9):1552-1558. doi: 10.1177/0961203318768890Rymarz A, Niemczyk S. The complex treatment including rituximab in the management of catastrophic antiphospholid syndrome with renal involvement. BMC Nephrol. 2018;19:132. doi: 10.1186/s12882-018-0928-zRymarz A, Niemczyk S. The complex treatment including rituximab in the management of catastrophic antiphospholid syndrome with renal involvement. BMC Nephrol. 2018;19:132. doi: 10.1186/s12882-018-0928-zGuillot M, Rafat C, Buob D, Coppo P, Jamme M, Rondeau E, et al. Eculizumab for catastrophic antiphospholipid syndrome – A case report and literature review. Rheumatology (Oxford). 2018;57(11):2055-2057. doi: 10.1093/rheumatology/key228Guillot M, Rafat C, Buob D, Coppo P, Jamme M, Rondeau E, et al. Eculizumab for catastrophic antiphospholipid syndrome – A case report and literature review. Rheumatology (Oxford). 2018;57(11):2055-2057. doi: 10.1093/rheumatology/key228Ruffatti A, Tarzia V, Fedrigo M, Calligaro A, Favaro M, Macor P, et al. Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab. Autoimmun Rev. 2019;18(5):561-563. doi: 10.1016/j.autrev.2019.03.015Ruffatti A, Tarzia V, Fedrigo M, Calligaro A, Favaro M, Macor P, et al. Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab. Autoimmun Rev. 2019;18(5):561-563. doi: 10.1016/j.autrev.2019.03.015Tinti MG, Carnevale V, Inglese M, Molinaro F, Bernal M, Migliore A, et al. Eculizumab in refractory catastrophic antiphospholipid syndrome: A case report and systematic review of the literature. Clin Exp Med. 2019;19(3):281-288. doi: 10.1007/s10238-019-00565-8Tinti MG, Carnevale V, Inglese M, Molinaro F, Bernal M, Migliore A, et al. Eculizumab in refractory catastrophic antiphospholipid syndrome: A case report and systematic review of the literature. Clin Exp Med. 2019;19(3):281-288. doi: 10.1007/s10238-019-00565-8Cavero T, Rabasco C, López A, Román E, Ávila A, Sevillano Á, et al. Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant. 2017;32(3):466-474. doi: 10.1093/ndt/gfw453Cavero T, Rabasco C, López A, Román E, Ávila A, Sevillano Á, et al. Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant. 2017;32(3):466-474. doi: 10.1093/ndt/gfw453Palma LMP, Sridharan M, Sethi S. Complement in secondary thrombotic microangiopathy. Kidney Int Rep. 2021;6:11-23. doi: 10.1016/j.ekir.2020.10.009Palma LMP, Sridharan M, Sethi S. Complement in secondary thrombotic microangiopathy. Kidney Int Rep. 2021;6:11-23. doi: 10.1016/j.ekir.2020.10.009Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169-2181. doi: 10.1056/NEJMoa1208981Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169-2181. doi: 10.1056/NEJMoa1208981de Holanda MI, Porto LC, Wagner T, Christiani LF, Palma LMP. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. Clin Rheumatol. 2017;36:2859-2867. doi: 10.1007/s10067-017-3823-2de Holanda MI, Porto LC, Wagner T, Christiani LF, Palma LMP. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. Clin Rheumatol. 2017;36:2859-2867. doi: 10.1007/s10067-017-3823-2Sciascia S, Radin M, Yazdany J, Tektonidou M, Cecchi I, Roccatello D, et al. Expanding the therapeutic options for renal involvement in lupus: Eculizumab, available evidence. Rheumatol Int. 2017;37(8):1249-1255. doi: 10.1007/s00296-017-3686-5Sciascia S, Radin M, Yazdany J, Tektonidou M, Cecchi I, Roccatello D, et al. Expanding the therapeutic options for renal involvement in lupus: Eculizumab, available evidence. Rheumatol Int. 2017;37(8):1249-1255. doi: 10.1007/s00296-017-3686-5

The authors declare that there are no conflicts of interest present.